Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | $0.00 | $70.0M |
| Operating income | -$8.90M | -$29.3M | -$69.6M | -$127M | -$92.8M | -$86.5M | -$78.8M | $12.5M |
| Operating margin | — | — | — | — | — | — | — | 17.9% |
| Net income | -$8.93M | -$35.3M | -$67.3M | -$126M | -$91.2M | -$82.4M | -$69.7M | $22.4M |
| Net margin | — | — | — | — | — | — | — | 32.0% |
| EPS (diluted) | -$4.42 | -$16.99 | -$2.05 | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.45M | -$24.7M | -$52.1M | -$100M | -$85.1M | -$66.7M | -$62.3M | $29.6M |
| Capital expenditures | $76.0K | $21.0K | $142K | $2.71M | $192K | $33.0K | $0.00 | — |
| Free cash flow | -$8.53M | -$24.7M | -$52.3M | -$103M | -$85.3M | -$66.8M | -$62.3M | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $51.7M | $155M | $34.6M | $65.8M | $34.3M | $56.2M | $36.4M | $21.0M |
| Total assets | $51.8M | $158M | $330M | $248M | $156M | $159M | $123M | $143M |
| Total liabilities | $6.60M | $4.88M | $21.9M | $51.8M | $40.6M | $41.8M | $39.4M | $30.8M |
| Shareholders' equity | -$15.5M | -$47.2M | $308M | $196M | $116M | $117M | $83.3M | $112M |
| Retained earnings | -$15.7M | -$51.0M | -$118M | -$244M | -$335M | -$417M | -$487M | -$465M |
| Shares (wtd avg diluted) | 2.17M | 2.24M | 32.9M | 36.2M | 36.3M | 44.0M | 55.0M | 57.6M |
Every figure is extracted from Black Diamond Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.